Gapping up
In reaction to strong earnings/guidance: RHT +5.9%, RAD +0.9%
M&A news: WCIC +36.7% (to be acquired by Lennar (LEN) in a cash and common stock transaction valued at $23.50/share), LEN +2.4%
Select financial related names showing strength: CS +3.3%, DB +3.2%, BCS +2.2%, SAN +2%, PUK +1.7%
Select metals/mining stocks trading higher: MT +4%, BBL +3.8%, FCX +3.6%, BHP +3.2%, RIO +3.2%, X +3%,AG +2.6%, GOLD +2.1%
Select oil/gas related names showing strength: STO +3%, BP +2.9%, WLL +2.8%, SDRL +2.4%, RDS.A +2.3%,CHK +2.2%, MRO +1.7%, TOT +0.9%
Other news: OCRX +18.8% (completes enrollment in STOP-ALF, a Phase 2a clinical trial to evaluate the Safety and Tolerability of Ornithine Phenylacetate in patients with Acute Liver Failure), AVXL +14.9% (presents preclinical data demonstrating that ANAVEX 2-73), URRE +9.6% (to acquire certain placer mining claims comprising the Sal Rica lithium brine project from Mesa Exploration), GALT +9.6% (following 35% move higher), NVAX +9.3% (Director disclosed purchase of 100K shares, worth total of $144.9K), NVAX +9.3% (following 30%+ move higher), TTOO +5.7% (presents data on the T2MR technology for the detection of Borrelia directly from whole blood samples at the Diagnostic Tests for Lyme Disease Conference), BSPM +4.5% (signs LOI to acquire 100% of equity interest in Xianyang Yongsheng in exchange for cash and issuance of shares of its restricted common stock), AQXP +3.2% (Baker Bros increases active stake to 45.1% ), IONS +3.1% (publication of key clinical results of two randomized controlled studies), HH +2.8% (announces a $1.8 mln private placement equity offering to certain accredited investors; co sold approx. 1.3 mln shares at $1.35/share), IRBT +2.8% (light volume - awarded $23 mln US Navy contract modification), FLEX +2.3% (favorable commentary on Wednesday's Mad Money), BUD +2.2% (still checking), KDMN +2.1% ( doses first patient in a Phase 2 clinical trial of KD025 for the treatment of chronic graft-versus-host disease; also initiates placebo-controlled Phase 2 clinical trial evaluating KD025 in Psoriasis), SRPT +1.8% ( announces a $225 mln underwritten public offering of common stock), CRM +1.8% (Salesforce.com and Cisco (CSCO) announce global strategic allianceg), ADMP +1.2% (Adamis Pharma higher on light volume as Mylan (MYL) CEO appears before Congress)
Analyst comments: FATE +6.6% (initiated with a Buy at ROTH Capital), PBYI +4.9% (target raised to $111 from $54 at Credit Suisse), TI +2.2% (upgraded to Outperform from Neutral at Macquarie), BABA +1.9% (target raised to $125 at Stifel), BLUE +1.7% (resumed with a Buy at ROTH Capital), AAPL +0.5% (target raised to $125 at RBC Capital Mkts; raised to $135 from $120 at Nomura)
In reaction to strong earnings/guidance: RHT +5.9%, RAD +0.9%
M&A news: WCIC +36.7% (to be acquired by Lennar (LEN) in a cash and common stock transaction valued at $23.50/share), LEN +2.4%
Select financial related names showing strength: CS +3.3%, DB +3.2%, BCS +2.2%, SAN +2%, PUK +1.7%
Select metals/mining stocks trading higher: MT +4%, BBL +3.8%, FCX +3.6%, BHP +3.2%, RIO +3.2%, X +3%,AG +2.6%, GOLD +2.1%
Select oil/gas related names showing strength: STO +3%, BP +2.9%, WLL +2.8%, SDRL +2.4%, RDS.A +2.3%,CHK +2.2%, MRO +1.7%, TOT +0.9%
Other news: OCRX +18.8% (completes enrollment in STOP-ALF, a Phase 2a clinical trial to evaluate the Safety and Tolerability of Ornithine Phenylacetate in patients with Acute Liver Failure), AVXL +14.9% (presents preclinical data demonstrating that ANAVEX 2-73), URRE +9.6% (to acquire certain placer mining claims comprising the Sal Rica lithium brine project from Mesa Exploration), GALT +9.6% (following 35% move higher), NVAX +9.3% (Director disclosed purchase of 100K shares, worth total of $144.9K), NVAX +9.3% (following 30%+ move higher), TTOO +5.7% (presents data on the T2MR technology for the detection of Borrelia directly from whole blood samples at the Diagnostic Tests for Lyme Disease Conference), BSPM +4.5% (signs LOI to acquire 100% of equity interest in Xianyang Yongsheng in exchange for cash and issuance of shares of its restricted common stock), AQXP +3.2% (Baker Bros increases active stake to 45.1% ), IONS +3.1% (publication of key clinical results of two randomized controlled studies), HH +2.8% (announces a $1.8 mln private placement equity offering to certain accredited investors; co sold approx. 1.3 mln shares at $1.35/share), IRBT +2.8% (light volume - awarded $23 mln US Navy contract modification), FLEX +2.3% (favorable commentary on Wednesday's Mad Money), BUD +2.2% (still checking), KDMN +2.1% ( doses first patient in a Phase 2 clinical trial of KD025 for the treatment of chronic graft-versus-host disease; also initiates placebo-controlled Phase 2 clinical trial evaluating KD025 in Psoriasis), SRPT +1.8% ( announces a $225 mln underwritten public offering of common stock), CRM +1.8% (Salesforce.com and Cisco (CSCO) announce global strategic allianceg), ADMP +1.2% (Adamis Pharma higher on light volume as Mylan (MYL) CEO appears before Congress)
Analyst comments: FATE +6.6% (initiated with a Buy at ROTH Capital), PBYI +4.9% (target raised to $111 from $54 at Credit Suisse), TI +2.2% (upgraded to Outperform from Neutral at Macquarie), BABA +1.9% (target raised to $125 at Stifel), BLUE +1.7% (resumed with a Buy at ROTH Capital), AAPL +0.5% (target raised to $125 at RBC Capital Mkts; raised to $135 from $120 at Nomura)